Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
21. Juli 2022 06:30 ET
|
Verve Therapeutics
CAMBRIDGE, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with...
Verve Therapeutics Announces Proposed Public Offering of Common Stock
20. Juli 2022 16:02 ET
|
Verve Therapeutics
CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with...
Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
20. Juli 2022 16:01 ET
|
Verve Therapeutics
BOSTON and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Verve Therapeutics, Inc. (Nasdaq: VERV) today announced an exclusive, four-year...
Verve Therapeutics Doses First Human with an Investigational In Vivo Base Editing Medicine, VERVE-101, as a Potential Treatment for Heterozygous Familial Hypercholesterolemia
12. Juli 2022 06:30 ET
|
Verve Therapeutics
Phase 1b Clinical Trial, heart-1, Now Underway and Enrolling Patients with Heterozygous Familial Hypercholesterolemia in New Zealand Company Executing VERVE-101 Global Regulatory Strategy with...
Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. “Bo” Cumbo, to its Board of Directors
13. Juni 2022 06:30 ET
|
Verve Therapeutics
CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
01. Juni 2022 06:30 ET
|
Verve Therapeutics
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results
10. Mai 2022 06:30 ET
|
Verve Therapeutics
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and...
Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at TIDES USA 2022
09. Mai 2022 06:30 ET
|
Verve Therapeutics
VERVE-101 Preclinical Data Package Supports Company’s Global Development Strategy and Regulatory Submissions for Clinical Trials in Patients with HeFH Single Intravenous Infusion of VERVE-101...
Verve Therapeutics to Participate in Upcoming May Investor Conferences
04. Mai 2022 06:30 ET
|
Verve Therapeutics
CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone Symposia
26. April 2022 06:30 ET
|
Verve Therapeutics
Extensive Analyses in Multiple Human Cell Types Demonstrate Minimal to No Off-target Editing Following VERVE-101 Treatment, Supporting its Planned Clinical Initiation in 2022 Whole Genome Sequencing...